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ow-Level Ionizing Radiation From Noninvasive
ardiac Imaging: Can We Extrapolate Estimated
isks From Epidemiologic Data to the
linical Setting?
arren K. Laskey, MD,* Ludwig E. Feinendegen, MD,†‡ Ronald D. Neumann, MD,§
asken Dilsizian, MD
lbuquerque, New Mexico; Düsselfdorf, Germany; Upton, New York; and Bethesda
nd Baltimore, Maryland
linical decision-making regarding the use of low-level ionizing radiation for diagnostic and/or therapeu-
ic purposes in patients with cardiovascular disease must, as in all other clinical scenarios, encompass the
road range of the risk–benefit ratio. Concerns regarding the late carcinogenic effects of exposure to low
evels, i.e.,100mSv, of ionizing radiation stem fromextrapolation of exposure-outcomedata in survivors
f WorldWar II atomic bomb explosions. However, ongoing debate regarding the true incremental risk to
ubjects exposed to doses currently administered in cardiovascular procedures fails to take into account
he uncertainty of the dose-response relationship in this lower range, as well as tissue-specific reparative
esponses, also manifest at lower levels of exposure. The present discussion draws attention to both of
hese aspects as they relate to clinical decision-making. (J AmColl Cardiol Img 2010;3:517–24) © 2010 by
he American College of Cardiology Foundationt
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linicians are constantly weighing the risk of a
rocedure, or treatment, against the benefit. In
eciding on the appropriate recommenda-
ion(s), the clinician resorts to the available
evidence”: that body of information derived
rom carefully obtained observations and mea-
urements that themselves have been tested for
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vidence is obtained from population-based
bservational or rigorous epidemiologic studies,
he conclusions and predictions made on the basis
f such observations will generally apply to an
average” member of a similar population. The
roblem arises when such population-derived
ata are then applied to an individual patient.
his classic dilemma of clinical decision-
aking is mitigated, but not obviated, when
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518ost of the patient’s characteristics match those of
he studied population. However, even under ideal
onditions of complete matching of such character-
stics, the predictive probability of an event (out-
ome) in a given individual will always be charac-
erized by greater uncertainty when compared to
he probability of an event in a large sample (Fig. 1).
Uncertainty in the estimate of risk must be
xpressed in conditional probabilistic terms. Distri-
utions for the parameter of interest, e.g., effective
ose (ED), should be explicitly presented as prob-
bility density functions. Point estimates and their
ssociated credible intervals should be reported.
erhaps the best example of this uncertainty is
emonstrated in the distinction between an “aver-
ge” subject and a subject with specific characteris-
ics exposed to ionizing radiation. This distinction
s at the heart of the application, or its failure, of
D at the level of the individual patient, or test.
he ED is, by definition, a calculated (as opposed
o measured) quantity that reflects the “average”
ge, “average” gender (realizing there cannot be
uch an entity), and “average” relative tissue radio-
sensitivities (tissue weighting factors) in a
given population exposed to a given
amount of ionizing radiation.
Table 1 summarizes the influence of age
and gender on the uncertainty in the risk
of cancer-related mortality, as presented in
the Biologic Effects of Ionizing Radiation
(BEIR) VII report (1). The 2% increase in
isk (relative risk [RR]: 1.02) associated with a dose
f 0.1 Gy differs significantly from the long-
tanding International Commission for Radiation
rotection–developed overall risk of 5% per Sievert
2). However, an order of magnitude of error in the
stimation of risk may not be unexpected when
oth exposure and risk are “low” and each is
haracterized by considerable uncertainty. For the
linician, the ED (and the associated risk of fatal
ancer) must be viewed in broader terms and should
ot be used to assess the risk of any 1 test involving
onizing radiation or the risk to any 1 patient. The
opulation-based data discussed earlier must be
nterpreted in that light, i.e., as population-based.
ncertainty in the “true” relationship between ab-
orbed dose and risk at low doses further removes
he concept of ED from a predictable single expo-
ure–single patient context.
If, then, the risk to the individual patient is
ncertain at low levels of ionizing radiation, the
otential benefit of the radiation-based procedure
r treatment must be clear-cut in order to effect eound decision-making. Unfortunately, too few
onizing radiation-based diagnostic or therapeutic
odalities have been subjected to the rigor of
andomized clinical trials. Although few would
rgue with a favorable risk–benefit ratio for cardiac
atheterization in the setting of acute ST-segment
levation myocardial infarction, where the life-
aving benefit of the procedure is immediate, clear-
ut, and overwhelmingly in favor of the procedure.
t the other end of the clinical spectrum is the
idespread use of computed tomography (CT)
canning as a screening tool in low- to medium-risk
ubjects in the general population. In this instance,
here virtually no data are available pointing to the
enefit of the procedure—either at the individual or
opulation level—the lack of objective benefit likely
quals (at best) or is less than (at worst) the
opulation attributable risk of cancer induction. In
real-world” clinical medicine, where the majority
f risk–benefit decision-making resides in a gray
rea, the lack of relevant data, clinical equipoise,
nd the level of clinical exigency characterize this
rocess. The difficulty in predicting risk for fatal
ancer 40 or 50 years following nonsurgical
atheter-based correction of a life-altering congen-
tal heart defect in a child might more properly be
onsidered in terms of years per life lost, or
isability-adjusted life years. Such approaches are
eeded for these gray areas where cancer-related
ortality is, practically speaking, a nonissue, but
orbidity and quality of life are very real, and
mmediate, issues for the individual patient. Con-
idering this background, a re-examination of the
asic concepts of the interaction of ionizing radia-
ion with tissue is in order.
he Concept(s) of Dose
bsorbed dose is defined as the amount of energy
ssociated with ionizing radiation that is deposited
er unit mass (of matter, tissue, etc.). The biological
azard of ionizing radiation is expressed as the ED
nd reflects not only the absorbed dose, but age at
xposure, gender, cellular radiosensitivity, the spe-
ific type of radiation and its “biological effective-
ess,” the population in which the biological se-
uelae were ascertained, and the mathematical
elationship between absorbed dose and biological
esponse. The terms absorbed dose and ED are,
nfortunately, often used interchangeably in the lay
ress as well as in the scientific literature. Although
bsorbed dose is the appropriate quantity to use forB B R E V I A T I O N S
N D A C R O N YM S
T computed tomography
D effective dosexperimental and epidemiologic analyses of dose-
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519esponse relationships, ED is the appropriate quan-
ity to use for the comparison of an exposure to
onizing radiation with regulatory dose limits based
n the risks of whole-body exposure (3). The risks,
owever, are based on mathematical modeling of
he rates of incident cancers mainly in the survivors
f the atomic bomb explosions as a function of
inferred) absorbed dose (4,5) and have been the
ubject of considerable discussion, if not frank
ontroversy, at absorbed doses 100 mGy. The
bsorbed dose of ionizing radiation for diagnostic
esting in cardiovascular medicine resides at the
ower end of this range and presents the greatest
hallenge for meaningful interpretation of the pre-
iously noted epidemiologic relationship between
ose and outcome. Thus, careful consideration of
he sources of uncertainty in the assessment of ED
s well as a more critical understanding of the
istinction between absorbed dose and ED is im-
erative for an informed discussion of the risks
ssociated with ionizing radiation for diagnostic
urposes (Table 2).
Table 3 summarizes approximate EDs for the
ost commonly performed diagnostic and thera-
eutic studies in cardiovascular medicine. However,
ngoing modifications in acquisition protocols for
ultidetector CT coronary angiography will result
n somewhat lower EDs than those reported (6).
dditionally, with current advances in both single-
hoton emission tomography and positron emission
omography instrumentation, diagnostic quality
mages can be acquired using nearly 50% of the
oses listed in Table 3.
omparison of High- Versus Low-Dose Ionizing
adiation Exposure
ll would agree that high values for absorbed doses
f ionizing radiation are harmful and result in acute
llness as well as late consequences, e.g., an elevated
isk of cancer decades after irradiation (7,8). In
ontrast, the situation is quite different for short- or
ong-term exposures to absorbed doses below about
00 mGy. Not only are acute illnesses absent at this
ose level, but late effects (such as cancer) have not
een observed in populations such as in Japan
ollowing the atom bomb explosions (3,4,9), in
ohorts of nuclear workers (10), or in populations
iving in geographic regions with high background-
evel radiation exposures (11).
The difficulty in attributing an increased risk of
ancer to low-dose exposure is due, in part, to the
elatively high incidence of nonradiogenic cancer inndustrialized countries as well as to the fact that
onizing radiation is a weak carcinogen, compared
o many other toxins to which humans are exposed.
espite the widespread belief that the majority of
ancer-related deaths following the atom bomb
xplosions in Hiroshima and Nagasaki were caused
y radiation, only 10% of the 3,350 identified
ancer-related deaths have been attributed to radi-
tion exposure (7). What was a good intention to
rotect workers from exposure to ionizing radiation
s beginning to cause widespread radiation phobia.
ven with no increase in cancer recognizable at
Predictive Probability Density
Posterior Probability Density
Figure 1. Probability Density Distributions
The upper panel demonstrates a hypothetical normal (beta) distrib
the posterior probability of a speciﬁc parameter, e.g., the risk of de
fatal cancer due to exposure to ionizing radiation. Such distribution
generated from the product of prior probabilities and a Bayes facto
lihood ratio, reﬂecting observed data, e.g., the Life Span Study coho
The lower panel demonstrates the hypothetical distribution for the
tive probability for the next observation. Notice the imprecision (ma
of standard deviation) in this quantity, reﬂecting uncertainty in the
the parameter coupled with uncertainty inherent in a single observ
Table 1. Estimated Lifetime Attributable Risk of Solid
Cancer-Related Mortality (With 95% Probability Interval)
Exposure
Mortality (per 100,000 Exposed)
Men Women
0.1 Gy to “general
population”
410 (200, 830) 610 (300, 1,230)
0.1 Gy at age 10 yrs 640 (300, 1,390) 1,050 (470, 2,330)
0.1 Gy at age 30 yrs 320 (150, 650) 490 (250, 950)ution for
ath from
s are
r, or like-
rt data.
predic-
gnitude
mean for0.1 Gy at age 50 yrs 290 (140, 600) 420 (210, 810)
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520oses below about 100 mSv, many patients seeking
edical help question the rationale of, and risk
rom, exposure to doses far below 100 mSv in the
ourse of diagnostic work-up. They fear cancer may
esult from being exposed. Such fears are re-
nforced by publications such as a recent appraisal
f medical radiation exposure that concluded that
.5% to 2% of all solid cancers in the U.S. might be
aused by the use of CT for diagnostic testing on a
idespread basis (12).
Only by way of modeling using certain assump-
ions, such as the linear no-threshold (LNT) hy-
othesis, can epidemiological data be made to fit
he notion that any amount of radiation absorbed by
he body potentially causes a malignant disease. The
NT hypothesis is widely accepted, and is the basis
or current radiation protection regulations and
uidelines, as suggested by the International Com-
ission for Radiation Protection (ICRP) for the
urpose of making sure that nobody suffers harm from
xposure to ionizing radiation (13). However, more
ecent discoveries on low-dose effects in biological
ystems challenge the validity of the model based on
his hypothesis.
NT Hypothesis Versus Radiation Hormesis
onizing radiation primarily perturbs the molecules
n cells in a manner proportional to dose, with
otential damage amplification at higher levels.
ellular defenses operate at each level, aimed at
cavenging of toxins, repair of damage (especially
hat of DNA), and removal of damaged compo-
ents with replacement of lost elements essential for
aintaining structural and functional integrity of
he organism. Whereas cancer was generally under-
tood to develop from primary and/or secondary
NA damage through cell transformation and
ubsequent stages to clinical malignancy in the face
f rather constant function of defense mechanisms
t the various levels, newer research indicates that
ow doses of ionizing radiation can upgrade these
rotective mechanisms to operate also against non-
e
ulombs/kg): sum energies of charged particles (ions) created by
g with a deﬁned unit of matter (e.g., air)
y; joule/kg): amount of energy deposited in unit mass of tissue
rbed dose (Sievert, Sv)
, Sv): (absorbed dose)  (radiation weighting factor speciﬁc for
v):  (dose equivalent)  (tissue weighting factor) summed overadiogenic, i.e., “spontaneous” cancer (14,15). Thisup-grading” of defenses, called adaptive protec-
ion, or radiation hormesis, functions under genetic
uidance against the abundant endogenous (mainly
etabolic) sources of DNA damage. A malignant
rocess occurs only when cells with unrepaired or
isrepaired DNA damage suffer malignant trans-
ormation and exceed the cellular and tissue func-
ions of protection. Therefore, the risk of clinical
ancer induction after low-dose irradiation appears
s the difference between the risk of induced cancer
alculated on the basis of the LNT hypothesis and
revented cancer from the aforementioned protec-
ive mechanisms.
amage to DNA and Its Repair
he immediate DNA damage and cellular re-
ponses to that damage include molecular cross-
inks of various kinds, base changes, sugar modifi-
ations, single-strand breaks, and the more serious
ouble-strand breaks (8). It needs be stressed that
he radiation-induced physicochemical damage to
NA increases linearly with dose. The reason for
his is the particular impact of ionizing radiation in
icrodose events in biological tissue. The spectrum
f these microdoses is characteristic for a given type
f radiation. As the radiation energy transfer in-
reases, the number of microdose events increases,
nd with them, the number of individual damage
ites caused by each one of the events. A dose effect
urve for chemical DNA damage in tissue actually
onforms to a linear “Impact-Number-Effectiveness
Table 3. Estimated ED (mSv) for Frequently Performed
Diagnostic and Therapeutic Cardiovascular Procedures
Procedure/Radionuclide
Dose
(mCi)
ED
(mSv)
201Thallium (stress–rest) 3.5 16.9
99mTc-Sestamibi (stress–rest) 27.5/10.0 10.7
99mTc-Tetrofosmin (stress–rest) 27.5/10.0 8.6
82Rubidium (stress–rest) 50/50 12.8
13N-ammonia (stress–rest) 15/15 2.3
18F-FDG 10.0 6.4
99mTc-labeled erythrocytes 22.5 5.7
CXR 0.1
MDCT–CA 15.0
Invasive–CA 7.0
PCI 15.0
RF arrhythmia ablation 15.0
Estimations take into consideration tissue weighting factors from the most
recent International Commission on Radiological Protection publication (Pub-
lication 103) for radiopharmaceuticals (28).
CA  coronary angiogram; CXR  chest roentgenogram; ED  effective
dose; FDG  ﬂuorodeoxyglucose; MDCT  multidetector computed tomog-
raphy; PCI  percutaneous coronary intervention; RF  radiofrequency; Tc Table 2. Nomenclatur
Exposure (kerma, k; co
photons interactin
Absorbed dose (gray, G
Biologic effects of abso
Dose equivalent (DE
type of radiation)
Effective dose (ED, Stechnetium.
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521unction” without threshold (16). This linear func-
ion, however, is not identical in all cell types due to
iffering genomic activity. Moreover, secondary
NA damage may arise in bystander cells and add
o the deviation from linearity.
Within minutes after irradiation, there is a
lethora of DNA and chromatin modification.
ithin 24 h after low-dose exposure, double-
trand breaks decrease in number, approaching
hat of the background “spontaneous” double-
trand breaks (17). At typical background radia-
ion levels, the probability of a radiation-induced
ouble-strand break per day per cell is, on aver-
ge, about 1 in 10,000 (18). The capacity of
ormal cells to repair damage to DNA and other
ellular components is genetically determined
nd may vary individually. More than 150 genes
ave been described in DNA repair at high and
ow doses (19,20). Some genes are active only in
ow-dose stress responses; others again are mod-
lated only after high doses (20,21). These data
ontradict a fundamental assumption of the LNT
ypothesis for assessing long-term health detri-
Single 
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A
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Figure 2. Schematic Representation of the Dual Response to Sin
Low doses of ionizing radiation can up-regulate physiological defen
defenses are also called adaptive protections and depend on dose
ranges from 0 to 1 and is Pap f (D; tp). The risk of radiation-induced
according to the linear no-threshold hypothesis and is expressed he
low-dose levels shown by light dotted lines: for cancer induction d
adaptive protections due to individual degrees of cellular responses
would at every dose level be the difference between radiogenic
product of the degree of protection and the value of the sponta
constant defenses in the system, from a single dose D, Pap f (D;
and time of effectiveness tp, Pspo  “spontaneous” life time canc
Adapted from data in Tubiana et al. (21).ent solely as function of dose. Moreover, low-
ose irradiated confluent cells in vitro appear to
tall DNA repair until cell proliferation begins
gain (17). Indeed, an immediate induction of
NA repair has been detected in proliferating
ells at low doses of about 1 mGy of X- and
amma radiation (21,22). In general, then, initial
onlethal radiation damage is answered in normal
ndividuals by immediate attempts at structural
econstitution with regained functional ho-
eostasis. Radiation effects involving DNA are
ltimately determined by the final extent of DNA
amage with sequence mutations and the protec-
ive response by the organism. Multiple malfunc-
ioning genes or gene cassettes are required for
ancer induction, invasion, and metastases to
ccur.
Figure 2 shows, as a function of dose, the 2
pposing effects: the risk of developing cancer and
he degree of adaptive protection against cancer,
ith the baseline showing the level of lifetime
onradiation-induced cancer that is observed in
ndustrialized countries. Whereas the degree of
e (Gy)
 Single Low-Doses
of Data
Pind
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Risk of Cancer Induction
Cancer at Constant Defenses
0.2 0.25 0.3
Low Doses
with delay with some lasting beyond a year. The up-regulated
d on the time tp of their action: the probability of protection
cer assumes constant defenses in the body at every dose D
y the value of Pind D. Both probabilities have uncertainties at
o bystander effects, genomic instability, induction of repair; for
e risk of cancer following a single low-dose exposure, therefore,
er risk and the prevented cancer risk, with the latter being the
us cancer risk. Pind D  radiation induced lethal cancer with
adaptive protection (0 to 1) in the system as function of D
isk of the exposed individual, in the industrialized world.Dos
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522rotection according to experimental observations
ises with increasing doses to a maximum at about
00 mGy and then falls toward 0 (23), the cancer
isk is given to rise linearly with dose if one assumes
hat existing protections against cancer are also
onstant at low doses in the exposed system. The
atter approach conforms to the LNT hypothesis.
he figure also includes detrimental bystander ef-
ects and consequences for cancer risk in the low-
ose range and also acknowledges immediate repair
nduction, as discussed earlier.
Calculations presented elsewhere show that a
ery small degree of increased protection, in the
egion of 2% of lifetime cancer risk, might be
ufficient to fully balance the assumed cancer risk at
00 mGy, based on the LNT hypothesis. Ongoing,
nd unresolved, controversy in the literature regard-
ng the differential risk of high- and low-dose
onizing radiation (24,25) has given rise to the
ypothesis that long-term, low doses of ionizing
adiation may actually be beneficial and may am-
lify or stimulate repair mechanisms that protect
gainst disease (21,23,26).
ncertainty in theMeasurements Themselves
tarting from classic epidemiologic studies and
rogressing through extensive experimental data,
t is clear that the probability of harm, expressed
s ED, is related in a complex fashion to the type
f radiation, the value of absorbed dose (and dose
ate), and tissue radiosensitivity. Confining the
linician’s concerns to the absorbed dose encoun-
ered in medical diagnostic imaging simplifies
hings somewhat but does not avoid dependence
n many assumptions. Although exposure (in
oentgen or air kerma) is directly translatable to
ose (Gy) for X-rays and gamma rays, the mea-
ure of the overall probability of harm is a
unction of (organ) dose conversion coefficients as
ell as tissue weighting factors. The former
peaks to geometrical considerations and the
patial relationship of the exposed tissue and the
fetime Attributable Risk for Exposure-Related Mortality From
ers
Men, per 100,000
Exposed (95%
Credible Interval)
Women, per 100,00
Exposed (95%
Credible Interval)
ths from
e to 0.1 Gy
410 (200, 830) 610 (300, 1200)
deaths in the
of exposure
22,100 17,500rimary radiation field, whereas the latter speakso the radiosensitivity of the irradiated tissue
tself. Thus, it is not surprising to see uncertain-
ies in the estimation of individual organ EDs
anging from 20% to 50% and that for a “repre-
entative” subject approaching 40%. An in-depth
iscussion of the assumptions and sources of error
n the estimation of ED is available elsewhere
27–29). However, several clinically relevant ca-
eats must be emphasized. Among these are the
ssues of single exposure versus multiple expo-
ures (with a corollary being the influence of
xposure rate), uniform exposure versus more
ocalized (heterogeneous) exposure, and the ap-
lication of atomic bomb survivor– derived risk
ata to the individual patient undergoing diag-
ostic testing.
Coupled with these uncertainties in dose is the
elationship of dose to risk. Ignoring for a mo-
ent the true shape of the population probability
istribution for survival, the LNT relationship
osits: 1) no “safe” dose; and 2) a finite, lifelong
isk for “low” doses, i.e., 100 mSv. It must be
ointed out, however, that the BEIR VII conclu-
ions in this regard may only be meaningful when
normal individual, belonging to a population of
00,000 individuals with an age distribution sim-
lar to the U.S. population, is exposed to a single
00 mGy dose. Once again, because risk is a
robabilistic concept, it must be expressed by a
istribution, or density, with a mean value and an
xpression of uncertainty: the standard deviation.
he uncertainty in the estimate of risk when
dded to the uncertainty inherent in fitting (sto-
hastic) data even to an assumed linear relation-
hip properly lends itself to a Bayesian approach.
or the clinician, the outcome of such a process is
tself uncertain. Thus, it comes as no surprise that
he credibility intervals for lifetime attributable
ancer risk, as presented in the BEIR VII report,
re wide (Table 4). Finally, although the LNT
elationship posits a linear relationship between
Table 5. Selected Relevant Exposures Found in Daily Living
Exposure
Average Individual
Effective Dose (mSv)
Trans-Atlantic airline ﬂight 0.1
Screening mammogram 3
Background “natural” radiation 3/yr
Dose over 70 yrs in Chernobyl 14
Radiation worker exposure limit 20/yr
Exposure on international space station 170/yr
Atom bomb survivors 200Table 4. Li
Solid Canc
Excess dea
exposur
Number ofNuclear workers 20
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523isk and dose at low exposure, i.e., 100 mSv, the
true” nature of this relationship in this lower
anges of radiation that are common for medical
ses of ionizing radiation (Table 3, diagnostic or
iagnostic/therapeutic exposure) is unknown, and
t may well display nonlinearities due to the
amage-limiting protective mechanisms dis-
ussed earlier.
onclusions
he clinician must understand that the prediction
f risk of a subsequent malignancy for an individual
ndergoing a medical diagnostic test, or procedure,
mploying ionizing radiation is a complex, uncer-
ain exercise. As with any risk calculation, “average”
isks obtained from population-based studies are of
ittle value for the individual. Population-based data
ust be weighted, or adjusted, for important clin-vention of the Council on Cardiovas-
Radiological Protec
cation 26. Ann ICRalignancy, especially at low dose and dose-rate;
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